製品名:4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid
IUPAC Name:(4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)boronic acid
| 包装単位 | 有効在庫 | 価格（USD） | 数量 |
|---|---|---|---|
| CM386131-1g | 3-4 Weeks | Ǡşƚ |
|
| CM386131-5g | 5-6 Weeks | ǺǠǺǠ |
|
|
|||
| Product Overview |
4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid, also known as MBOB, is a boronic acid derivative that has gained significant attention in recent years due to its potential applications in medicinal chemistry. MBOB is a heterocyclic compound that contains both boronic acid and oxazine moieties, making it a versatile molecule for various chemical reactions. |
| Synthesis and Application |
The synthesis of 4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid involves the condensation reaction of 2-amino-4-methylphenol with salicylic aldehyde in the presence of boron trifluoride etherate. The resulting intermediate is then treated with sodium borohydride to obtain 4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid. The yield of 4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid can be improved by optimizing the reaction conditions, such as the reaction time, temperature, and solvent. 4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid has been studied for its potential applications in medicinal chemistry, particularly as an antitumor agent. 4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid has been shown to inhibit the growth of various cancer cell lines, including breast, lung, and colon cancer cells. 4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid exerts its antitumor activity by inducing apoptosis, inhibiting cell proliferation, and suppressing tumor angiogenesis. 4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid has also been investigated for its antibacterial and antifungal properties. |
| Future Directions |
Future research on 4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid could focus on improving its pharmacokinetic properties, such as increasing its half-life and bioavailability. Other future directions could include investigating the potential of 4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid as a combination therapy with other antitumor agents or exploring its antibacterial and antifungal properties further. Additionally, the mechanism of action of 4-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic Acid could be elucidated further to better understand its antitumor activity. |
検索 
+86 21 5895 0110 
